{"analyses":[{"ciLowerLimit":"0.78","ciNumSides":"TWO_SIDED","ciPctValue":"95.1","ciUpperLimit":"1.36","estimateComment":"Stratified Cox proportional hazard model.","groupDescription":"Hazard Ratio is Nivolumab 3 mg/kg (IV) over Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","paramType":"Hazard Ratio (HR)","paramValue":"1.03"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"2.33","upperLimit":"3.52","value":"3.12"},{"groupId":"OG001","lowerLimit":"2.30","upperLimit":"5.29","value":"3.65"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"272"},{"groupId":"OG001","value":"133"}],"units":"Participants"}],"description":"Progression Free Survival (PFS) is defined as the time from randomization to the date of the first documented progression, as determined by the Independent Review Committee (IRC) using RECIST 1.1, or death due to any cause, whichever occurs first. Participants who died without a reported progression were considered to have progressed on the date of their death. Participants who did not progress or die were censored on the date of their last evaluable tumor assessment before subsequent anti-cancer therapy. Unit of measure (months) is the median survival time.","dispersionType":"95% Confidence Interval","groups":[{"description":"Nivolumab 3 mg/kg IV over 60 minutes Q2W","id":"OG000","title":"Nivolumab"},{"description":"Dacarbazine: 1000 mg/m\\^2 IV Q3W Carboplatin: Area under the concentration-time curve (AUC) 6 IV Q3W Paclitaxel: 175 mg/m\\^2 IV Q3W","id":"OG001","title":"Investigator's Choice (Dacarbazine or Carboplatin+Paclitaxel)"}],"paramType":"MEDIAN","populationDescription":"All randomized participants","reportingStatus":"POSTED","timeFrame":"From the date of randomization to the date of the first documented progression or death (Up to approximately 38 months)","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}